On the back of its strong financial performance in 2014, Amgen, the Tri-Counties’ largest private employer, is set to begin shifting research operations away from its Thousand Oaks headquarters.
[wikichart align=”right” ticker=”NASDAQ:AMGN” showannotations=”true” livequote=”true” startdate=”27-04-2014″ enddate=”27-10-2014″ width=”300″ height=”245″] Cost cutting moves and new drugs are starting to pay off for Amgen Inc., as the biotech giant raised earnings guidance after a stronger-than-expected third quarter. The company said Oct. 27 that strong demand for its white blood cell booster, Neulasta, and increased sales of newer Read More →
By Editorial Board / Friday, October 24th, 2014 / Editorials, Opinion / Comments Off on Editorial: Ebola eradication effort turns to region’s experts
In the case of Direct Relief and Amgen, their efforts to bring the Ebola outbreak under control may be more than noteworthy. They may help make history.
Despite a record drought, short-sighted policy making and a slow-to-start generation of self-established young workers, the outlook for Ventura County is bright. “It should be another year of expansion — you pretty much count on that — and no recession in sight, at least not yet,” said Mark Schniepp, director of the California Economic Forecast. Read More →
Atara is among a new breed of “virtual” biotech startups. Such firms operate with barebones staff and outsource research and manufacturing operations to contract organizations. They are becoming increasingly common as investors seek to mitigate the huge risks of bringing drugs to market, a process that can cost as much as $1.8 billion, according to industry estimates.
